Feynman Kac Reweighted Schr\"odinger Bridge Matching for Surface-Based Tau PET Harmonization
arXiv:2606.17420v1 Announce Type: cross Abstract: Tau PET imaging is central to tracking Alzheimer's disease progression, but systematic differences between scanners, protocols, and radiotracers across sites introduce nonbiological variability that inflates biomarker variance, reduces sensitivity to disease effects, and can bias downstream clinical assessments. Harmonization methods aim to remove these site-induced shifts while preserving biologically meaningful signal, yet existing approaches struggle when source and target cohorts differ in subgroup composition, risking conflation of site ef
The increasing prevalence of multi-site neuroimaging studies in Alzheimer's disease research necessitates robust methods for harmonizing data to ensure consistent and reliable biomarker analysis.
Accurate and harmonized neuroimaging data is crucial for developing effective diagnostic tools and treatments for neurodegenerative diseases, impacting pharmaceutical development and public health strategies.
Improved harmonization techniques for medical imaging can reduce methodological variability, leading to more precise disease tracking and potentially accelerating therapeutic breakthroughs.
- · Alzheimer's Disease Researchers
- · Medical Imaging Companies
- · Pharmaceutical Industry
- · Patients with Neurodegenerative Diseases
More reliable and consistent insights from multi-site clinical trials and observational studies of Alzheimer's disease.
Accelerated development and validation of new diagnostic biomarkers and therapeutic interventions for neurodegenerative disorders.
Enhanced global collaboration in medical research due to standardized data, fostering more comprehensive understanding of complex diseases.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.AI